Abstract
In late 2002 a new disease, severe atypical respiratory syndrome (SARS), emerged in China. A hitherto unknown animal coronavirus (CoV) that had crossed the species barrier through close contact of humans with infected animals was identified as the etiological agent. It rapidly adapted to the new host and not only became readily transmissible between humans but also more pathogenic. Air travel spread it rapidly around the world and ultimately the virus infected 8096 people and caused 774 deaths in 26 countries on 5 continents. Aggressive quarantine measures successfully terminated the disease. Currently, there are no SARS cases recorded and most likely the virus no longer circulates in the human population. In this review we present an overview over SARS-Co virus biology, the disease and discuss strategies to develop antiviral drugs and vaccines.
Keywords: Coronaviruses, SARS-CoV, cellular entry point, transcription regulatory sequences (TRSs), Replicase Polyproteins
Current Molecular Medicine
Title: SARS: Understanding the Virus and Development of Rational Therapy
Volume: 5 Issue: 7
Author(s): K. Stadler and R. Rappuoli
Affiliation:
Keywords: Coronaviruses, SARS-CoV, cellular entry point, transcription regulatory sequences (TRSs), Replicase Polyproteins
Abstract: In late 2002 a new disease, severe atypical respiratory syndrome (SARS), emerged in China. A hitherto unknown animal coronavirus (CoV) that had crossed the species barrier through close contact of humans with infected animals was identified as the etiological agent. It rapidly adapted to the new host and not only became readily transmissible between humans but also more pathogenic. Air travel spread it rapidly around the world and ultimately the virus infected 8096 people and caused 774 deaths in 26 countries on 5 continents. Aggressive quarantine measures successfully terminated the disease. Currently, there are no SARS cases recorded and most likely the virus no longer circulates in the human population. In this review we present an overview over SARS-Co virus biology, the disease and discuss strategies to develop antiviral drugs and vaccines.
Export Options
About this article
Cite this article as:
Stadler K. and Rappuoli R., SARS: Understanding the Virus and Development of Rational Therapy, Current Molecular Medicine 2005; 5 (7) . https://dx.doi.org/10.2174/156652405774641124
DOI https://dx.doi.org/10.2174/156652405774641124 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Big Pharma's Recent Challenges
Applied Clinical Research, Clinical Trials and Regulatory Affairs Editorial [Hot topic: MicroRNAs: from Basic Regulation Towards Therapeutic Approaches - Passion, Caution and Patience Required (Guest Editor: Dr. Thomas Thum)]
Current Drug Targets Air Pollution and Lung Cancer
Current Respiratory Medicine Reviews Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS)
Recent Patents on Anti-Cancer Drug Discovery CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry How Does HIV Cause Depletion of CD4 Lymphocytes? A Mechanism Involving Virus Signaling Through its Cellular Receptors
Current Molecular Medicine Longevity Depends on a Balance Between Proinflammatory and Anti-Inflammatory Factors: Use of Tcms and Natural Products
Current Drug Discovery Technologies Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology Lipoprotein-Associated Phospholipase A2: How Effective as a Risk Marker of Cardiovascular Disease and as a Therapeutic Target?
Inflammation & Allergy - Drug Targets (Discontinued) Premature Ageing Prevention: Limitations and Perspectives of Pharmacological Interventions
Current Drug Targets Safety Considerations in the Use of Ketorolac for Postoperative Pain
Current Drug Safety Cardiovascular Disease and Inflammation: Novel Biomarkers of Inflammation and Endothelial Activation
Vascular Disease Prevention (Discontinued) Thymosin β4 Protein Therapy for Cardiac Repair
Current Pharmaceutical Design Solution NMR Study of the Transmembrane Domain of Single-Span Membrane Proteins: Opportunities and Strategies
Current Protein & Peptide Science Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry An update on the Management and Treatment of Deep Vein Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design Endocannabinoid Blockade and the Cardiovascular System
Current Drug Therapy The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes
Current Protein & Peptide Science